An organic electroluminescence device includes: an anode; a cathode; a first emitting layer; and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer contains, as a first host material, a first compound that has at least one group represented by a formula (11A) below and that is represented by a formula (1) below, the second emitting layer contains, as a second host material, a second compound represented by a formula (2) below, and the first emitting layer and the second emitting layer are in direct contact with each other

##STR00001##

An organic electroluminescence device includes: an anode; a cathode; a first emitting layer; and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer contains, as a first host material, a first compound that has at least one group represented by a formula (11) below and that is represented by a formula (1) below, the second emitting layer contains, as a second host material, a second compound represented by one of formulae (2-1A) to (2-4A) below, and the first emitting layer and the second emitting layer are in direct contact with each other.

##STR00001## ##STR00002##

An organic electroluminescence device includes: an anode; a cathode; a first emitting layer; and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer contains, as a first host material, a first compound that has at least one group represented by a formula (11) below and that is represented by a formula (1) below, the second emitting layer contains, as a second host material, a second compound represented by one of formulae (2-1A) to (2-4A) below, and the first emitting layer and the second emitting layer are in direct contact with each other.

##STR00001## ##STR00002##

A porphyrin compound of Formula III ##STR00001## and composition made therefrom comprising a therapeutically effective dose of a porphyrin bound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may be delivered by a drug delivery device as disclosed here and be part of a kit.

A porphyrin compound of Formula III ##STR00001## and composition made therefrom comprising a therapeutically effective dose of a porphyrin bound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may be delivered by a drug delivery device as disclosed here and be part of a kit.

This invention relates to compounds and compositions useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.

This invention relates to compounds and compositions useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.

The present invention relates to compounds that are useful as radioimaging agents and radiopharmaceuticals. The compounds may be coordinated with a radionuclide and may be useful in diagnostic imaging and radiotherapy. The invention also relates to methods of prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

This invention relates to atroipsomers of reduced tetraphenylporphyrin derivatives with halogen atoms (F, Cl, Br) in the ortho positions of the phenyl groups, particularly halogenated tetraphenylchlorins and halogenated tetraphenylbacteriochlorins, which can be used in photodynamic therapy. According to the formulae of the invention, the ortho-phenyl substituents X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, X.sup.6, X.sup.7 and X.sup.8 may be identical or different and represent halogen atoms or hydrogen atoms, provided that at least all of X.sup.2, X.sup.4, X.sup.6 and X.sup.8 are halogens, and the meta-phenyl substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently chosen from —OH, —OR or —SO.sub.2R″, where R″ are each independently chosen from —Cl, —OH, -aminoacid, —OR, —NHR, or —NR.sub.2, where R are alkyl of 1 to 12 carbon atoms or R.sub.2 represents cycloalkyl with 2 to 12 carbon atoms. The atropisomers of this invention have the majority of the substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 on the same side of the plane defined by the macrocycle. The invention also relates to an anticancer and/or antimicrobial and/or antiviral pharmaceutical composition where atropisomers α.sub.4 and α.sub.3β are the main active ingredients, such that the mixture of atropisomers α.sub.4 and α.sub.3β constitutes more than 70% of the atropisomers present in the active ingredient and/or the atropisomer α.sub.4 constitutes more than 20% of the atropisomers present in the pharmaceutical composition.

This invention relates to atroipsomers of reduced tetraphenylporphyrin derivatives with halogen atoms (F, Cl, Br) in the ortho positions of the phenyl groups, particularly halogenated tetraphenylchlorins and halogenated tetraphenylbacteriochlorins, which can be used in photodynamic therapy. According to the formulae of the invention, the ortho-phenyl substituents X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, X.sup.6, X.sup.7 and X.sup.8 may be identical or different and represent halogen atoms or hydrogen atoms, provided that at least all of X.sup.2, X.sup.4, X.sup.6 and X.sup.8 are halogens, and the meta-phenyl substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently chosen from —OH, —OR or —SO.sub.2R″, where R″ are each independently chosen from —Cl, —OH, -aminoacid, —OR, —NHR, or —NR.sub.2, where R are alkyl of 1 to 12 carbon atoms or R.sub.2 represents cycloalkyl with 2 to 12 carbon atoms. The atropisomers of this invention have the majority of the substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 on the same side of the plane defined by the macrocycle. The invention also relates to an anticancer and/or antimicrobial and/or antiviral pharmaceutical composition where atropisomers α.sub.4 and α.sub.3β are the main active ingredients, such that the mixture of atropisomers α.sub.4 and α.sub.3β constitutes more than 70% of the atropisomers present in the active ingredient and/or the atropisomer α.sub.4 constitutes more than 20% of the atropisomers present in the pharmaceutical composition.